AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON announced expanded analytical data showing 98% sequence coverage and 100% amino acid identity for its lead asset ABP-450 compared to BOTOX across all regions analyzed. Preliminary disulfide bond characterization confirmed the critical C430-C454 bond architecture is preserved in both products.
Key figures
- Amino acid identity
- 100%
- Disulfide bond abundance
- 99%
- Sequence coverage active neurotoxin
- 98%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.